1.

) GENERIC NAME: GABAPENTIN

BRAND NAME: Neurontin, Gabarone
CLASSIFICATION: CENTRAL NERVOUS SYSTEM AGENT; ANTICONVULSANT,
GABA ANALOG
DOSAGE: 100mg/tab
ROUTE AND FREQUENCY: Once a day via Oral
MECHANISM OF ACTION:
Gabapentin is a GABA neurotransmitter analog; however, it does not interact with
GABA receptors, and it does not inhibit GABA uptake or degradation. Mechanism of
action is unknown. An effect of gabapentin on central serotonin metabolism has been
postulated.
INDICATION:
Adjunctive therapy for partial seizures with or without secondary generalization in
adults, post-herpetic neuralgia. Add-on therapy for generalized seizures, peripheral
neuropathy, migraine prophylaxis.
CONTRAINDICATION:
Hypersensitivity or allergy to any components in the formulation.
ADVERSE EFFECT:
 CNS: Drowsiness, fatigue, dizziness, tremor, slurred speech, impaired
concentration, headache, increased frequency of partial seizures.
 Endocrine: Weight gain. GI: Nausea, gastric upset, vomiting. 
 Special Senses: Blurred vision, nystagmus, 
 Skin: Rash, eczema.

NURSING RESPONSIBILITIES
 Monitor for therapeutic effectiveness; may not occur until several weeks following
initiation of therapy.
 Assess frequency of seizures: In rare cases, the drug has increased the
frequency of partial seizures.
 Assess safety: Vision, concentration, and coordination may be impaired by
gabapentin.
2.) GENERIC NAME: TRAMADOL HYDROCHLORIDE
BRAND NAME: Ultram, Zydol
CLASSIFICATION: CENTRAL NERVOUS SYSTEM (CNS)
AGENT; ANALGESIC; NARCOTIC (OPIATE) AGONIST
DOSAGE: 1 tab
ROUTE AND FREQUENCY: Three times a day for 5 days - Oral
MECHANISM OF ACTION:
Centrally acting opiate receptor agonist that inhibits the uptake of norepinephrine and
serotonin, suggesting both opioid and nonopioid mechanisms of pain relief. May
produce opioid-like effects, but causes less respiratory depression than morphine.
INDICATION:
Management of moderate to moderately severe pain.
CONTRAINDICATION:
Hypersensitivity to tramadol or other opioid analgesics; patients on MAO inhibitors;
patients acutely intoxicated with alcohol, hypnotics, centrally acting analgesics, opioids,
or psychotropic drugs; substance abuse; patients on obstetric preoperative medication;
abrupt discontinuation; alcohol intoxication; pregnancy (category C); lactation; children
<16 y.
ADVERSE EFFECT:
 CNS: Drowsiness, dizziness, vertigo, fatigue, headache,
somnolence, restlessness, euphoria, confusion, anxiety, coordination
disturbance, sleep disturbances, seizures.
 CV: Palpitations, vasodilation. 
 GI: Nausea, constipation, vomiting, xerostomia, dyspepsia, diarrhea, abdominal
pain, anorexia, flatulence. 
 Body as a Whole: Sweating, anaphylactic reaction (even with first dose),
withdrawal syndrome (anxiety, sweating, nausea, tremors, diarrhea, piloerection,
panic attacks, paresthesia, hallucinations) with abrupt discontinuation. 
 Skin: Rash. Special Senses: Visual disturbances.
 Urogenital: Urinary retention/frequency, menopausal symptoms.

NURSING RESPONSIBILITIES
 Assess for level of pain relief and administer prn dose as needed but not to
exceed the recommended total daily dose.
 Monitor vital signs and assess for orthostatic hypotension or signs of CNS
depression.
 Discontinue drug and notify physician if S&S of hypersensitivity occur.
 Assess bowel and bladder function; report urinary frequency or retention.
 Use seizure precautions for patients who have a history of seizures or who are
concurrently using drugs that lower the seizure threshold.
 Monitor ambulation and take appropriate safety precautions.
  Ask the parent of the patient to notify any of the health care team if the patient
vomits of having abdominal pain
 Monitor for signs and symptoms of adverse reaction.

3.) GENERIC NAME: PARACETAMOL

BRAND NAME: Tylenol
CLASSIFICATION: NONNARCOTIC ANALGESIC, ANTIPYRETIC
DOSAGE: 500mg tab PRN
ROUTE AND FREQUENCY: four times a day via Oral
MECHANISM OF ACTION:
Produces analgesia by unknown mechanism, perhaps by action on peripheral nervous
system. Reduces fever by direct action on hypothalamus heat-regulating center with
consequent peripheral vasodilation, sweating, and dissipation of heat. Unlike aspirin,
acetaminophen has little effect on platelet aggregation, does not affect bleeding time,
and generally produces no gastric bleeding.
INDICATION:
Fever reduction. Temporary relief of mild to moderate pain. Generally, as a substitute
for aspirin when the latter is not tolerated or is contraindicated.
CONTRAINDICATION:
Hypersensitivity or allergy to any components in the formulation.
ADVERSE EFFECT:
 Body as a Whole: Negligible with recommended dosage;
 Acute poisoning: Anorexia, nausea, vomiting, dizziness, lethargy, diaphoresis,
chills, epigastric or abdominal pain, diarrhea;
 onset of hepatotoxicity—elevation of serum transaminases (ALT, AST) and
bilirubin;
 hypoglycemia, hepatic coma, acute renal failure (rare). 
 Chronic ingestion: Neutropenia, pancytopenia, leukopenia, thrombocytopenic
purpura, hepatotoxicity in alcoholics, renal damage.
NURSING RESPONSIBILITIES
 Monitor for S&S of: hepatotoxicity, even with moderate acetaminophen doses,
especially in individuals with poor nutrition or who have ingested alcohol over
prolonged periods; poisoning, usually from accidental ingestion or suicide
attempts; potential abuse from psychological dependence (withdrawal has been
associated with restless and excited responses).
  Do not take other medications (e.g., cold preparations) containing
acetaminophen without medical advice; overdosing and chronic use can cause
liver damage and other toxic effects.
 Do not self-medicate adults for pain more than 10 d (5 d in children) without
consulting a physician.
 Do not use this medication without medical direction for: fever persisting longer
than 3 d, fever over 39.5° C (103° F), or recurrent fever.
 Do not give children more than 5 doses in 24 h unless prescribed by physician.
 Do not breast feed while taking this drug without consulting physician.

4.) GENERIC NAME: LACTULOSE

BRAND NAME: Cephulac, Chronulac
CLASSIFICATION: GASTROINTESTINAL AGENT; HYPEROSMOTIC LAXATIVE
DOSAGE: 30cc
ROUTE AND FREQUENCY: Once a day - Oral
MECHANISM OF ACTION:
Reduces blood ammonia; appears to involve metabolism of lactose to organic acids by
resident intestinal bacteria
INDICATION:
Prevention and treatment of portal-systemic encephalopathy (PSE), including stages of
hepatic precoma and coma, and by prescription for relief of chronic constipation.
CONTRAINDICATION:
Low galactose diet; pregnancy (category C). Safe use in lactation or children is not
established.
ADVERSE EFFECT:
 GI: Flatulence, borborygmi, belching, abdominal cramps, pain, and distention
(initial dose); diarrhea (excessive dose); nausea, vomiting, colon accumulation of
hydrogen gas; hypernatremia.

NURSING RESPONSIBILITIES
 In children if the initial dose causes diarrhea, dosage is reduced immediately.
Discontinue if diarrhea persists.
 Promote fluid intake ( 1500–2000 mL/d) during drug therapy for constipation;
older adults often self-limit liquids. Lactulose-induced osmotic changes in the
bowel support intestinal water loss and potential hypernatremia. Discuss strategy
with physician.
  Laxative action is not instituted until drug reaches the colon; therefore, about 24–
48 h is needed.
 Do not self-medicate with another laxative due to slow onset of drug action.
 Notify physician if diarrhea (i.e., more than 2 or 3 soft stools/d) persists more
than 24–48 h. Diarrhea is a sign of overdosage. Dose adjustment may be
indicated.
.

5.) GENERIC NAME: FeSO4 + Folic Acid

BRAND NAME: Fer-Iron
CLASSIFICATION: BLOODS FORMERS, COAGULATORS, AND
ANTICOAGULANTS; IRON PREPARATION
DOSAGE: 1 Tab
ROUTE AND FREQUENCY: Three times a day - Oral
MECHANISM OF ACTION:
Ferrous sulfate corrects iron-deficiency anemia by providing iron necessary for the
production of haemoglobin and certain iron containing enzymes and by resaturating iron
storage organs. Iron is irregularly and incompletely absorbed from the gastrointestinal
tract, the main sites of action being the duodenum and jejunum. Absorption is increased
in conditions of iron deficiency or when given in fasting state.
INDICATION:
To correct simple iron deficiency and to treat iron deficiency (microcytic, hypochromic)
anemias. Also may be used prophylactically during periods of increased iron needs, as
in infancy, childhood, and pregnancy.
CONTRAINDICATION:
Peptic ulcer, regional enteritis, ulcerative colitis; hemolytic anemias (in absence of iron
deficiency), hemochromatosis, hemosiderosis, patients receiving repeated transfusions,
pyridoxine-responsive anemia; cirrhosis of liver.

ADVERSE EFFECT:
GI: Nausea, heartburn, anorexia, constipation, diarrhea, epigastric pain, abdominal
distress, black stools. 
Special Senses: Yellow-brown discoloration of eyes and teeth (liquid forms.) Large
Chronic Doses in Infants Rickets (due to interference with phosphorus
absorption). Massive Overdosage Lethargy, drowsiness, nausea, vomiting, abdominal
pain, diarrhea, local corrosion of stomach and small intestines, pallor or cyanosis,
metabolic acidosis, shock, cardiovascular collapse, convulsions, liver necrosis, coma,
renal failure, death.
NURSING RESPONSIBILITIES
 note: ascorbic acid increases absorption of iron. consuming citrus fruit or tomato
juice with iron preparation (except the elixir) may increase its absorption.
 be aware that milk, eggs, or caffeine beverages when taken with the iron
preparation may inhibit absorption.
 be aware that iron preparations cause dark green or black stools.
 report constipation or diarrhea to physician; symptoms may be relieved by
adjustments in dosage or diet or by change to another iron preparation.

6.) GENERIC NAME: CIPROFLOXACIN

BRAND NAME: Cipro
CLASSIFICATION: ANTIINFECTIVE; QUINOLONE ANTIBIOTIC
DOSAGE: 500mg/tab
ROUTE AND FREQUENCY: Twice a day for 7 days - Oral
MECHANISM OF ACTION:
Synthetic quinolone that is a broad spectrum bactericidal agent. Inhibits DNA-gyrase, an
enzyme necessary for bacterial DNA replication and some aspects of transcription,
repair, recombination, and transposition.
INDICATION:
UTIs, lower respiratory tract infections, skin and skin structure infections, bone and joint
infections, GI infection or infectious diarrhea, chronic bacterial prostatitis, nosocomial
pneumonia, acute sinusitis. Post-exposure prophylaxis for anthrax. Ophthalmic: Corneal
ulcers, bacterial conjunctivitis caused by Staphylococci,
Streptococci, and Pseudomonas aeruginosa.
CONTRAINDICATION:
Known hypersensitivity to ciprofloxacin or other quinolones, syphilis, viral infection;
tendon inflammation or tendon pain; pregnant women (category C), lactation.

ADVERSE EFFECT:
GI: Nausea, vomiting, diarrhea, cramps, gas, pseudomembranous colitis. 
Metabolic: Transient increases in liver transaminases, alkaline phosphatase, lactic
dehydrogenase, and eosinophilia count. 
Musculoskeletal: Tendon rupture, cartilage erosion. 
CNS: Headache, vertigo, malaise, peripheral neuropathy, seizures (especially with rapid
IV infusion). 
Skin: Rash, phlebitis, pain, burning, pruritus, and erythema at infusion site. 
Special Senses: Local burning and discomfort, crystalline precipitate on superficial
portion of cornea, lid margin crusting, scales, foreign body sensation, itching, and
conjunctival hyperemia.
NURSING RESPONSIBILITIES
 Report tendon inflammation or pain. Drug should be discontinued.
 Lab tests: Culture and sensitivity tests should be done prior to initial dose.
Treatment may be implemented pending results.
 Monitor urine pH; it should be less than 6.8, especially in the older adult and
patients receiving high dosages of ciprofloxacin, to reduce the risk of crystalluria.
 Monitor I&O ratio and patterns: Patients should be well hydrated; assess for S&S
of crystalluria.
 Monitor plasma theophylline concentrations, since drug may interfere with half-
life.
 Administration with theophylline derivatives or caffeine can cause CNS
stimulation.
 Assess for S&S of GI irritation (e.g., nausea, diarrhea, vomiting, abdominal
discomfort) in clients receiving high dosages and in older adults.
 Monitor PT and INR in patients receiving coumarin therapy.
 Assess for S&S of superinfections


7.) GENERIC NAME: Ampicillin

BRAND NAME: Ampicin
CLASSIFICATION: ANTIINFECTIVE; ANTIBIOTIC; AMINOPENICILLIN
DOSAGE: 2 grams
ROUTE AND FREQUENCY: Every 6 hours - IV
MECHANISM OF ACTION:
A broad-spectrum semisynthetic, aminopenicillin is highly bactericidal even at low
concentrations, but is inactivated by penicillinase (beta-lactamase).
INDICATION:
Infections of GU, respiratory, and GI tracts and skin and soft tissues; also gonococcal
infections, bacterial meningitis, otitis media, sinusitis, and septicemia and for
prophylaxis of bacterial endocarditis. Used parenterally only for moderately severe to
severe infections.
CONTRAINDICATION:
Hypersensitivity to penicillin derivatives; infectious mononucleosis.
ADVERSE EFFECT:
 Body as a Whole: Similar to those for penicillin G. Hypersensitivity (pruritus,
urticaria, eosinophilia, hemolytic anemia, interstitial nephritis, anaphylactoid
reaction); superinfections. 
 CNS: Convulsive seizures with high doses. 
  GI: Diarrhea, nausea, vomiting, pseudomembranous colitis. Other: Severe pain
(following IM); phlebitis (following IV). 
 Skin: Rash.

NURSING RESPONSIBILITIES
 Determine previous hypersensitivity reactions to penicillins, cephalosporins, and
other allergens prior to therapy.
 Lab tests: Baseline C&S tests prior to initiation of therapy; start drug pending
results. Baseline and periodic assessments of renal, hepatic, and hematologic
functions, particularly during prolonged or high-dose therapy.
 Note: Sodium content of drug must be considered in patients on sodium
restriction.
 Inspect skin daily and instruct patient to do the same. The appearance of a rash
should be carefully evaluated to differentiate a nonallergenic ampicillin rash from
a hypersensitivity reaction. Report rash promptly to physician.
 Note: Incidence of ampicillin rash is higher in patients with infectious
mononucleosis or other viral infections, Salmonella infections, lymphocytic
leukemia, or hyperuricemia or in patients taking allopurinol.
 Take medication around the clock; continue taking medication until it is all gone
(usually 10 d) unless otherwise directed by physician or pharmacist.

8.) GENERIC NAME: Levofloxacin

BRAND NAME: Levaquin
CLASSIFICATION: ANTIINFECTIVE; ANTIBIOTIC; QUINOLONE
DOSAGE: 750mg/tab
ROUTE AND FREQUENCY: Once a day - Oral
MECHANISM OF ACTION:
A broad-spectrum fluoroquinolone antibiotic that inhibits DNA-gyrase, an enzyme
necessary for bacterial replication, transcription, repair, and recombination.
INDICATION:
Treatment of maxillary sinusitis, acute exacerbations of bacterial bronchitis, community-
acquired pneumonia, uncomplicated skin/skin structure infections, UTI, acute
pyelonephritis caused by susceptible bacteria; acute bacterial sinusitis; chronic bacterial
prostatitis; bacterial conjunctivitis.

CONTRAINDICATION:
Hypersensitivity to levofloxacin and quinolone antibiotics; hypokalemia, tendon pain,
pregnancy (category C); syphilis; viral infections; phototoxicity; lactation.
ADVERSE EFFECT:
  CNS: Headache, insomnia, dizziness. 
 GI: Nausea, diarrhea, constipation, vomiting, abdominal pain, dyspepsia. 
 Skin: Rash, pruritus. 
 Special Senses: Decreased vision, foreign body sensation, transient ocular
burning, ocular pain, photophobia. Urogenital: Vaginitis. 
 Body as a Whole: Injection site pain or inflammation, chest or back pain, fever,
pharyngitis. 
 Other: Cartilage erosion.

NURSING RESPONSIBILITIES
 Lab tests: Do C&S test prior to beginning therapy and periodically.
 Withhold therapy and report to physician immediately any of the following: Skin
rash or other signs of a hypersensitivity reaction (see Appendix F); CNS
symptoms such as seizures, restlessness, confusion, hallucinations, depression;
skin eruption following sun exposure; symptoms of colitis such as persistent
diarrhea; joint pain, inflammation, or rupture of a tendon; hypoglycemic reaction
in diabetic on an oral hypoglycemic agent.

9.) GENERIC NAME Tranexamic Acid

BRAND NAME: Cyklokapron
CLASSIFICATION: BLOOD FORMERS, COAGULATORS, AND
ANTICOAGULANTS; HEMOSTATIC
DOSAGE: 500 mg
ROUTE AND FREQUENCY: Every 8 hours for 3 doses - IV
MECHANISM OF ACTION:
Tranexamic acid inhibits fibrinolysis by blocking the binding of plasminogen and plasmin
to fibrin, thus preventing dissolution of the haemostatic plug.
INDICATION:
Short-term management of haemorrhage
CONTRAINDICATION:
Hypersensitivity. Active thromboembolic disease (e.g. pulmonary embolism, DVT),
history of venous or arterial thrombosis (including retinal vein or artery occlusion),
disseminated intravascular coagulation, fibrinolytic conditions after consumption
coagulopathy, history of convulsions. Concomitant use with hormonal contraceptives.
Severe renal impairment.

ADVERSE EFFECT:
 Significant: Visual and ocular disturbance (e.g. impaired colour vision), retinal
vein or artery occlusion, ligneous conjunctivitis, thromboembolic events,
 convulsions.

 Blood and lymphatic system disorders: Anaemia

.
Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain.

General disorders and administration site conditions: Fatigue.

Musculoskeletal and connective tissue disorders: Musculoskeletal pain,
muscle cramps.

Nervous system disorders Headache, migraine.

Respiratory, thoracic and mediastinal disorders: Nasal and sinus symptoms
 .
Potentially Fatal: Severe hypersensitivity reactions including anaphylaxis

NURSING RESPONSIBILITIES
 Check IV site at frequent intervals for extravasation.
 Observe for signs of thrombophlebitis. Change site immediately if extravasation
or thrombophlebitis occurs (see Appendix F).
 Monitor & report S&S of myopathy: muscle weakness, myalgia, diaphoresis,
fever, reddish-brown urine (myoglobinuria), oliguria, as well as thrombotic
complications: arm or leg pain, tenderness or swelling, Homan's sign,
prominence of superficial veins, chest pain, breathlessness, dyspnea. Drug
should be discontinued promptly.
 Monitor vital signs and urine output.
 Lab tests: with prolonged therapy, monitor creatine phosphokinase activity and
urinalyses for early detection of myopathy.

10.) GENERIC NAME: EPERISONE

BRAND NAME:
CLASSIFICATION: ANTISPASMODIC
DOSAGE: 1 tab
ROUTE AND FREQUENCY: Three times a day for five days - Oral
MECHANISM OF ACTION:
Eperisone is centrally-acting agent which relaxes skeletal muscles by inhibition of
experimentally-induced muscle rigidity, suppression of spinal reflexes and reduction of
muscle spindle sensitivity via y-motor neurons. It also dilates vascular smooth muscles
and augments blood flow.
INDICATION:
Muscle Spasms
CONTRAINDICATION:
Hypersensitivity or allergy to any components in the formulation.

ADVERSE EFFECT:
 Significant: Shock, anaphylaxis reactions (e.g. redness, itching, urticaria,
oedema, dypnoea), Stevens-Johnson syndrome and toxic epidermal necrolysis.
 Blood and lymphatic system disorders: Anaemia.
 Cardiac disorders: Palpitations.
 Gastrointestinal disorders: Nausea, vomiting, stomach discomfort, abdominal
pain, diarrhoea, constipation, stomatitis, feeling of enlarged abdomen, hiccup.
 General disorders and admin site conditions: Weakness, fatigue, diaphoresis.
 Investigations: Elevated BUN.
 Metabolism and nutrition disorders: Anorexia, thirst.
 Musculoskeletal and connective tissue disorders: Stiffness, muscle
hypotonia.
 Nervous system disorders: Headache, numbness of extremities, tremor, light-
headedness, dizziness.
 Psychiatric disorders: Sleepiness, insomnia.
 Renal and urinary disorders: Proteinuria, urinary retention, urinary
incontinence.
 Skin and subcutaneous tissue disorders: Rash, pruritus, erythema exudative
multiforme.
 Vascular disorders: Hot flushes.

NURSING RESPONSIBILITIES

 Be aware that incidence and severity of adverse effects are usually dose related
and may be minimized by dosage reduction. Older adults appear more sensitive
to usual adult doses.
 Monitor vital signs. Pulse is a particularly sensitive indicator of response to drug.
Report tachycardia, palpitations, paradoxical bradycardia, or fall in BP.
 Assess for and report severe CNS stimulation (see ADVERSE EFFECTS) that
occurs with high doses, and in patients with arteriosclerosis, or those with history
of hypersensitivity to other drugs.
 In patients with severe rigidity, tremors may appear to be accentuated during
therapy as rigidity diminishes.
 Monitor daily I&O if patient develops urinary hesitancy or retention. Voiding
before taking drug may relieve problem.
 Check for abdominal distention and bowel sounds if constipation is a problem.
 Monitor intraocular pressure at regular intervals.
 Provide close follow-up care. Tolerance may develop, necessitating dosage
adjustment or use of combination therapy. Patients  60 y frequently develop
sensitivity to drug action.
BLOOD TRANSFUSION
Date: January 11, 2020 @ 2300H

Patient’s Blood Type: O+

Donor’s Blood Type: O+
Serial Number: 9000-007888-4
Segment No: IO9U5512
Blood Comp: PRBC
Blood Amount: 289 mL
Blood Bank: PRC
Date of Collection: December 14, 2020
Date of Expiration: January 18, 2020
Interpretation: COMPATIBLE

BLOOD TRANSFUSION
Date: January 11,2020 @ 2330H

Patient’s Blood Type: O+

Donor’s Blood Type: O+
Serial Number: 9000-002081-4
Segment No: Q0672848
Blood Comp: PRBC
Blood Amount: 287 mL
Blood Bank: PRC
Date of Collection: January 08, 2020
Date of Expiration: February 12, 2020
Interpretation: COMPATIBLE

BLOOD TRANSFUSION
Date: January 11, 2020 @2330H

Patient’s Blood Type: O+

Donor’s Blood Type: O+
Serial Number: 9000-000058-4
Segment No: Q0672764
Blood Comp: PRBC
Blood Amount: 285 mL
Blood Bank: PRC
Date of Collection: January 08, 2020
Date of Expiration: February 12, 2020
Interpretation: COMPATIBLE

BLOOD TRANSFUSION
Date: January 13, 2020 @1730H

Patient’s Blood Type: O+

Donor’s Blood Type: O+
Serial Number: 9000-007390-4
Segment No: I10U4433
Blood Comp: PRBC
Blood Amount: 330 mL
Blood Bank: PRC
Date of Collection: December 12, 2020
Date of Expiration: January 16, 2020
Interpretation: COMPATIBLE

BLOOD TRANSFUSION
Date: January 14, 2020

Patient’s Blood Type: O+

Donor’s Blood Type: O+
Serial Number: 9000- 007447-4
Segment No: Q0618515
Blood Comp: PRBC
Blood Amount: 284 mL
Blood Bank: PRC
Date of Collection: January 13, 2020
Date of Expiration: February 17, 2020
Interpretation: COMPATIBLE

BLOOD TRANSFUSION
Date: January 21, 2020 @2200H

Patient’s Blood Type: O+

Donor’s Blood Type: O+
Serial Number: 9000-008361-4
Segment No: Q0845789
Blood Comp: FWB
Blood Amount: 450 mL
Blood Bank: PRC
Date of Collection: January 17, 2020
Date of Expiration: February 21, 2020
Interpretation: COMPATIBLE